Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.30 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884595 | 0.91 | ALDH1A1 (0.39) | ALDH1A1LMNATSHRPOLBPOLA1 | |
| SCHEMBL1881184 | 0.81 | GPR84 (0.38) | ALDH1A1LMNATAS1R3TAS1R1 | |
| SCHEMBL473860 | 0.76 | ALDH1A1 (0.42) | ALDH1A1LMNATSHRABCB1 | |
| SCHEMBL28647767 | 0.75 | ZDHHC7 (0.40) | ALDH1A1LMNATSHRTAS1R3TAS1R1 | |
| SCHEMBL1884184 | 0.73 | ALDH1A1 (0.40) | ALDH1A1LMNATSHR | |
| SCHEMBL18204068 | 0.73 | ALDH1A1 (0.40) | ALDH1A1LMNATSHR | |
| SCHEMBL976764 | 0.73 | ALDH1A1 (0.46) | ALDH1A1LMNATSHRPOLBPOLA1 | |
| SCHEMBL18076264 | 0.73 | ALDH1A1 (0.46) | ALDH1A1LMNATSHRPOLBPOLA1 | |
| SCHEMBL1886494 | 0.73 | ALDH1A1 (0.37) | ALDH1A1LMNAABCB1 | |
| SCHEMBL473862 | 0.72 | GAA (0.36) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2657219-A1 | Intermediate for producing bicyclic y-amino acid derivative | Daiichi Sankyo Company, Limited (JP) | 2013-10-30 | — | — | EP | disclosed |
| EP-2192109-B1 | BICYCLIC -AMINO ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-7947738-B2 | Bicyclic γ-amino acid derivative | DAIICHI SANKYO COMPANY, LTD. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-20100249229-A1 | BICYCLIC gamma-AMINO ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2192109-A1 | BICYCLIC -AMINO ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249229-A1 | BICYCLIC gamma-AMINO ACID DERIVATIVE | GLRA2, GLRB, BCAT1 | ALDH1A1 521/4885LMNA 2607/4885TSHR 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.